Literature DB >> 31338571

Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone.

Shih-Hsin Liang1, Su-Peng Yeh2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31338571     DOI： 10.1007/s00277-019-03761-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  6 in total

Review 1.  TEMPI Syndrome: Update on Clinical Features, Management, and Pathogenesis.

Authors:  Jian Xu; Wenqi Liu; Fengjuan Fan; Bo Zhang; Fei Zhao; Yu Hu; Chunyan Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-19       Impact factor: 6.055

Review 2.  Diagnosis and management of monoclonal gammopathy of clinical significance.

Authors:  Hyungwoo Cho
Journal:  Blood Res       Date:  2022-04-30

3.  Diffuse telangiectasia: A clue to the TEMPI syndrome.

Authors:  Yeping Ruan; Xiaoqing Zhao; Meng Pan
Journal:  JAAD Case Rep       Date:  2021-02-27

4.  Ocular involvement in TEMPI syndrome.

Authors:  Jo-Hsuan Wu; Narine Viruni; Justin Chun; Satish Shanbhag; T Y Alvin Liu
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-10

Review 5.  Cutaneous manifestations of monoclonal gammopathy.

Authors:  Jean-Sebastien Claveau; David A Wetter; Shaji Kumar
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

6.  Case Report: TEMPI syndrome: Report of three cases and treatment follow-up.

Authors:  Zhuo-Fan Xu; Jing Ruan; Long Chang; Sijin Wu; Jinkai Lin; Wei Wang; XinXin Cao; Lu Zhang; Jian Li; Daobin Zhou; Wei Zhang
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.